Jupiter Wellness (NASDAQ:JUPW) Stock Attempts To Rebound: How Far Can it Go?
Patients with mild to moderate eczema will be treated with JW-100 lotion as part of leading skin care therapeutics and treatments company, Jupiter Wellness (NASDAQ:JUPW) updated on 13th July demonstrating head-to-head trial comparing JW-100 lotion with Eucrisacrisaborole ointment.
Eucrisa, an FDA-approved topical non-steroidal lotion, has crisaborolethat has permitted for treating such patients and JW-100 is a unique non-steroidal topical lotion having Aspertame andcannabidiol for the treatment. The trial will assess superiority between JW-100 and Eucrisa in adult patients and will done together with Applied Biology. Applied Biology has made the protocols and will be responsible for coordination.
The company had reporter earlier on a double-blinded, placebo controlled clinical trial of 55 patients using JW-100, which demonstrated reduction in eczema after two weeks of use.
Dr. Glynn Wilson Chief Scientific Officer at Jupiter Wellness, said that the company is committed on giving quick and consistent relief for eczema patients and the results give strong evidence to advance the clinical program.
Brian John, Jupiter Wellness’ CEO, said that the purpose of the trial is to confirm effectiveness in a bigger population mass and the company’s aim to commercialize both OTC and prescription versions of JW-100. John added that the latest licensing of Photocilgives a novel opportunity for combining therapies including am/pm eczema treatment regimines.
Market Reaction:
On Tuesday, JUPW stock gained 0.66% at $4.61 with more than 145k shares, compared to its average volume of 149K shares. The stock had moved within a range of $4.4400 – 4.6100 after opening the trade at $4.58. Over the past 52-week, the stock has been trading within a range of $3.6000 – 8.8800.
